Genmab (Otc) ((GMAB)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab is conducting a first-in-human clinical trial titled ‘First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors.’ The study aims to assess the safety, pharmacokinetics, and efficacy of GEN1047, a bispecific antibody, in treating solid tumors. This trial is significant as it explores a novel therapeutic approach for patients with limited treatment options.
The intervention being tested is GEN1047, a biological bispecific antibody designed to induce T-cell mediated cytotoxicity in B7H4-positive tumor cells. It is administered via intravenous infusion, with dose levels determined through escalation steps during the trial.
The study follows an open-label, sequential intervention model without masking, focusing primarily on treatment. It includes two phases: dose escalation to determine safety and optimal dosing, followed by an expansion phase to test up to two doses.
The trial began on December 13, 2021, with a primary completion date yet to be reached. The last update was submitted on August 4, 2025. These dates are crucial for tracking the progress and potential outcomes of the study.
This update could positively impact Genmab’s stock performance and investor sentiment, as successful results may enhance the company’s competitive edge in the oncology market. Investors should monitor this trial closely, considering the potential implications for the broader industry.
The study is ongoing, with further details available on the ClinicalTrials portal.